Evidence map›Paper›PMID 36405967›Full record

ArticleFrontiers in cellular and infection microbiology2022

SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR-based genotyping offers comparable performance to whole genome sequencing.

Simone Vanoni, Arnoldas Matulevicius, Besard Avdiu, Giada Scantamburlo, Camilla Ulekleiv, Pius M Brzoska, Manohar R Furtado, Jelena D M Feenstra, Alain Rico, Manoj Gandhi and 4 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simone VanoniPharmGenetix GmbH, Niederalm/Anif, Austria.
Arnoldas MatuleviciusPharmGenetix GmbH, Niederalm/Anif, Austria.
Besard AvdiuPharmGenetix GmbH, Niederalm/Anif, Austria.
Giada ScantamburloPharmGenetix GmbH, Niederalm/Anif, Austria.
Camilla UlekleivThermo Fisher Scientific, South San Francisco, CA, United States.
Pius M BrzoskaThermo Fisher Scientific, South San Francisco, CA, United States.
Manohar R FurtadoThermo Fisher Scientific, South San Francisco, CA, United States.
Jelena D M FeenstraThermo Fisher Scientific, South San Francisco, CA, United States.
Alain RicoThermo Fisher Scientific, South San Francisco, CA, United States.
Manoj GandhiThermo Fisher Scientific, South San Francisco, CA, United States.
Elisabetta GiacobazziAzienda sanitaria dell'Alto Adige, Laboratorio di microbiologia e virologia, Bolzano, Italy.
Elisa MasiAzienda sanitaria dell'Alto Adige, Laboratorio di microbiologia e virologia, Bolzano, Italy.
Markus PaulmichlDepartment of Personalised Medicine, Privatklinik Maria Hilf GmbH, Klagenfurt, Austria.
Charity NofzigerPharmGenetix GmbH, Niederalm/Anif, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Known SARS-CoV-2 variants of concern (VOCs) can be detected and differentiated using an RT-PCR-based genotyping approach, which offers quicker time to result, lower cost, higher flexibility, and use of the same laboratory instrumentation for detection of SARS-CoV-2 when compared with whole genome sequencing (WGS). In the current study, we demonstrate how we applied a genotyping approach for identification of all VOCs and that such technique can offer comparable performance to WGS for identification of known SARS-CoV-2 VOCs, including more recent strains, Omicron BA.1 and BA.2.

Indexed as

COVID-19SARS-CoV-2GenotypeHumansReverse Transcriptase Polymerase Chain ReactionWhole Genome SequencingalphaCOVID-19deltamutation panelomicronSARS-CoV-2variants of concernwhole genome sequencing

Identifiers

PMID36405967
PMCPMC9670535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.